Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Cancer Research
|
February 13, 2025
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
Nealia C House, Victoria E Brown, Maxine Chen, et al.
ACS Chemical Biology
|
November 10, 2015
Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates
P Ann Boriack-Sjodin, Lei Jin, Suzanne L Jacques, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 19, 2015
Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652
Nathalie Rioux, Lorna H Mitchell, Philip Tiller, et al.
SLAS Discovery : Advancing Life Sciences R & D
|
October 6, 2019
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity
Shane M Buker, Zachary A Gurard-Levin, Benjamin D Wheeler, et al.
Plos One
|
January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Plos One
|
July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
NPJ Breast Cancer
|
December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
Nealia C House, Maxine M Chen, Sima Khazaei, et al.
ACS Medicinal Chemistry Letters
|
November 19, 2025
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement
Brian A Sparling, Hyelee Lee, Mary-Margaret Zablocki, et al.
Cancer Cell
|
February 16, 2017
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E Gardner, Benjamin H Lok, Valentina E Schneeberger, et al.
The Lancet. Oncology
|
April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Cancer Research
|
February 13, 2025
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
Nealia C House, Victoria E Brown, Maxine Chen, et al.
ACS Chemical Biology
|
November 10, 2015
Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates
P Ann Boriack-Sjodin, Lei Jin, Suzanne L Jacques, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 19, 2015
Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652
Nathalie Rioux, Lorna H Mitchell, Philip Tiller, et al.
SLAS Discovery : Advancing Life Sciences R & D
|
October 6, 2019
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity
Shane M Buker, Zachary A Gurard-Levin, Benjamin D Wheeler, et al.
Plos One
|
January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Plos One
|
July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
NPJ Breast Cancer
|
December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
Nealia C House, Maxine M Chen, Sima Khazaei, et al.
ACS Medicinal Chemistry Letters
|
November 19, 2025
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement
Brian A Sparling, Hyelee Lee, Mary-Margaret Zablocki, et al.
Cancer Cell
|
February 16, 2017
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E Gardner, Benjamin H Lok, Valentina E Schneeberger, et al.
The Lancet. Oncology
|
April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Page
of 3